Company Filing History:
Years Active: 2019-2021
Title: Innovations of Ungsik Yu in Cancer Treatment
Introduction
Ungsik Yu is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compositions. With a total of three patents to his name, Yu's work focuses on utilizing microRNA for therapeutic purposes.
Latest Patents
One of his latest patents is titled "Double-stranded oligo RNA structure comprising miRNA." This invention relates to a double-stranded oligo RNA structure that includes double-stranded miRNA, aimed at preventing or treating cancer. Specifically, it involves an anti-cancer pharmaceutical composition that contains a double-stranded oligo RNA structure comprising miR-3670, miR-4477, and miR-8078. This composition is characterized by its effectiveness in inhibiting cancer cell proliferation and inducing cancer cell apoptosis.
Another significant patent is the "Pharmaceutical composition for treating cancer comprising microRNA as active ingredient." This invention includes a pharmaceutical composition for cancer treatment, which features one or more miRNAs selected from miR-3670, miR-8078, and miR-4477a as active ingredients. The composition demonstrates excellent effects in inhibiting cancer cell proliferation and inducing apoptosis, making it a promising anticancer therapeutic agent.
Career Highlights
Ungsik Yu is currently associated with Bioneer Corporation, where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential impact on cancer treatment methodologies.
Collaborations
Yu collaborates with notable colleagues, including Taewoo Lee and Sanghyung Shim, who contribute to his research endeavors.
Conclusion
Ungsik Yu's innovative work in the field of cancer treatment through microRNA technology showcases his dedication to advancing medical science. His patents reflect a commitment to developing effective therapeutic solutions for cancer patients.